Life-Sciences-Asia.com
The Asian Life Sciences Web Portal

This is a free web portal for the life sciences in Asia... » read more

Kupando Raises €13m Series A Led by Remiges Ventures (2022-09-26)
> Financing led by Remiges Ventures, co-led by LifeCare Partners, with additional investments by Brandenburg Kapital, High-Tech Gründerfonds, Ventura Biomed Investors and undisclosed family offices. > Proceeds to be used to complete IND-enabling work and initiat...
GSK Licenses Late-stage Antibiotic from Spero Therapeutics (2022-09-22)
> The exclusive licence allows GSK to commercialise tebipenem HBr in all regions except for Japan and certain other Asian countries > Spero Therapeutics receives $66 million upfront, with potential for future milestone payments and tiered royalties > GSK to p...
Merck Opens € 29m Biologics Testing Center in Shanghai (2022-09-21)
> First-of-its-kind facility for Merck in China to meet local demand > New lab marks completion of phase 1 of company’s new Biologics Testing Center > Phase 2 to include expansion of cell line characterization and lot release testing services Merck, a le...
Nuvisan: $9.6m for Non-hormonal Contraceptive Medicines (2022-09-20)
NUVISAN’s integrated drug discovery expertise leveraged in a grant from the Bill & Melinda Gates Foundation NUVISAN ICB GmbH, a fully integrated contract research service provider for drug discovery and development (“NUVISAN ICB”), announced today that the com...
Perfect Day Discloses Partnership with Onego Bio (2022-09-20)
Company unveils enterprise biology partnership with Onego Bio, to accelerate scaling of animal-free egg white protein production. Today, global biotechnology leader Perfect Day announces the new brand identity of its enterprise biology business — nth Bio — and...
Heidelberg Pharma: Takeda Exercises License Option for ATAC (2022-09-09)
Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH and Takeda signed a license agreement granting Takeda an exclusive license to commercially develop an Antibody Targeted Amanitin Conjugate directed to a previously ...
QLi5 Therapeutics Attracts €10m in Series A Financing (2022-09-07)
Development of Novel Proteasome Inhibitors for treating cancer, inflammatory and autoimmune disorders Qli5 Therapeutics GmbH (QLi5), a German-Korean joint venture developing a new class of proteasome inhibitors, has closed a EUR 10 million series A financing r...
Arsenal Biosciences Closes $220m Series B Financing (2022-09-06)
Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced the close of a $220 million Series B financing round. New investors Softbank Vision Fund 2, Bristol-Mye...
Dammam Valley Acquires Majority Share in Arcensus (2022-09-05)
Dammam Valley/KSA to acquire the majority of Arcensus GmbH/Germany to accelerate the global implementation of Whole Genome Sequencing in genetic diagnostics and delivery of breakthrough technologies in genomic bioinformatics With a cross-functional, internationa...
Evotec to Acquire Central Glass Germany for € 1 (2022-08-25)
> EXPANSION OF CGMP DRUG SUBSTANCE MANUFACTURING PLATFORM WILL CREATE A CLEAR PATH TO THE MARKET FOR RARE DISEASES AND PRECISION THERAPEUTICS > EVOTEC GAINS A FULLY OPERATIONAL EU GMP CERTIFIED FACILITY IN HALLE/WESTPHALIA ALONG WITH A HIGHLY SKILLED TEAM OF APP...

Life-Sciences-Asia.com is your doorway to the Asian life sciences!

[LSA] provides free, up-to-date and structured access to

– News
– Products
– Persons
– Organisations
– Financings
– Collaborations

in the Asian region.

Access is unrestricted and free, requiring no log in and no user registration.The high-quality content is not related to the advertising, with topical relevance being the criterion for inclusion. [LSA] is 100% Made in Germany!

» Start here with the latest News!

Picture Berlin Partner Health Capital Computational Biology 2022 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]